Your browser doesn't support javascript.
loading
The prevalence and mortality risks of PRISm and COPD in the United States from NHANES 2007-2012.
Cadham, Christopher J; Oh, Hayoung; Han, MeiLan K; Mannino, David; Cook, Steven; Meza, Rafael; Levy, David T; Sánchez-Romero, Luz María.
Afiliação
  • Cadham CJ; School of Public Health, Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
  • Oh H; Georgetown University-Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Han MK; Division of Pulmonary and Critical Care, University of Michigan Health System, Ann Arbor, MI, USA.
  • Mannino D; Division of Pulmonary and Critical Care Medicine, University of Kentucky, Lexington, KY, USA.
  • Cook S; COPD Foundation, Miami, FL, USA.
  • Meza R; School of Public Health, Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.
  • Levy DT; BC Cancer Research Institute, Vancouver, Canada.
  • Sánchez-Romero LM; Georgetown University-Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Respir Res ; 25(1): 208, 2024 May 15.
Article em En | MEDLINE | ID: mdl-38750492
ABSTRACT

BACKGROUND:

We estimated the prevalence and mortality risks of preserved ratio impaired spirometry (PRISm) and chronic obstructive pulmonary disease (COPD) in the US adult population.

METHODS:

We linked three waves of pre-bronchodilator spirometry data from the US National Health and Nutritional Examination Survey (2007-2012) with the National Death Index. The analytic sample included adults ages 20 to 79 without missing data on age, sex, height, BMI, race/ethnicity, and smoking status. We defined COPD (GOLD 1, 2, and 3-4) and PRISm using FEV1/FVC cut points by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). We compared the prevalence of GOLD stages and PRISm by covariates across the three waves. We estimated adjusted all-cause and cause-specific mortality risks by COPD stage and PRISm using all three waves combined.

RESULTS:

Prevalence of COPD and PRISm from 2007-2012 ranged from 13.1%-14.3% and 9.6%-10.2%, respectively. We found significant differences in prevalence by sex, age, smoking status, and race/ethnicity. Males had higher rates of COPD regardless of stage, while females had higher rates of PRISm. COPD prevalence increased with age, but not PRISm, which was highest among middle-aged individuals. Compared to current and never smokers, former smokers showed lower rates of PRISm but higher rates of GOLD 1. COPD prevalence was highest among non-Hispanic White individuals, and PRISm was notably higher among non-Hispanic Black individuals (range 31.4%-37.4%). We found associations between PRISm and all-cause mortality (hazard ratio [HR] 2.3 95% CI 1.9-2.9) and various cause-specific deaths (HR ranges 2.0-5.3). We also found associations between GOLD 2 (HR 2.1, 95% CI 1.7-2.6) or higher (HR 4.2, 95% CI 2.7-6.5) and all-cause mortality. Cause-specific mortality risk varied within COPD stages but typically increased with higher GOLD stage.

CONCLUSIONS:

The prevalence of COPD and PRISm remained stable from 2007-2012. Greater attention should be paid to the potential impacts of PRISm due to its higher prevalence in minority groups and its associations with mortality across various causes including cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inquéritos Nutricionais / Doença Pulmonar Obstrutiva Crônica Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Respir Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inquéritos Nutricionais / Doença Pulmonar Obstrutiva Crônica Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Respir Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos